MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy

C. Vilariño-Güell; A. I. Soto-Ortolaza; A. Rajput; D. C. Mash; S. Papapetropoulos; R. Pahwa; K. E. Lyons; R. J. Uitti; Z. K. Wszolek; D. W. Dickson; M. J. Farrer; O. A. Ross

doi:10.1212/WNL.0b013e31820c30c1

MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy

C. Vilariño-Güell, A. I. Soto-Ortolaza, A. Rajput, D. C. Mash, S. Papapetropoulos, R. Pahwa, K. E. Lyons, R. J. Uitti, Z. K. Wszolek, D. W. Dickson, M. J. Farrer, O. A. Ross

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Original language	English (US)
Pages (from-to)	670-672
Number of pages	3
Journal	Neurology
Volume	76
Issue number	7
DOIs	https://doi.org/10.1212/WNL.0b013e31820c30c1
State	Published - Feb 15 2011

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.0b013e31820c30c1

Cite this

@article{9bd38c748fa948b994858d0f12543780,

title = "MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy",

author = "C. Vilari{\~n}o-G{\"u}ell and Soto-Ortolaza, {A. I.} and A. Rajput and Mash, {D. C.} and S. Papapetropoulos and R. Pahwa and Lyons, {K. E.} and Uitti, {R. J.} and Wszolek, {Z. K.} and Dickson, {D. W.} and Farrer, {M. J.} and Ross, {O. A.}",

note = "Funding Information: Disclosure: Dr. Vilari{\~n}o-G{\"u}ell and Dr. Soto-Ortolaza report no disclosures. Dr. Rajput has served on scientific advisory boards for Novartis and UCB; has received funding for travel and speaker honoraria from Novartis; serves on the editorial board of the Canadian Journal of Neurological Sciences; and has received research support from Novartis, Allergan Inc., the NIH (NINDS U01 NS050324-01A1 [local PI]), CIHR, International Essential Tremor Foundation, Regina Curling Classic for Parkinson's Research, and Parkinson's disease and movement disorders endowment through RUH Foundation. Dr. Mash serves on scientific advisory boards for NIH PMDA, Boris Sokolov, and SRA; has received funding for travel or speaker honoraria from the Institute for the Prevention of In Custody Deaths; has patents pending re: Noribogaine and Biomarkers of Parkinson disease; is employed as Chief Scientific Officer for DEMERx Inc., and serves as a consultant for Phylogeny, Inc. Dr. Papapetropoulos serves as Associate Editor for Yearbook of Neurology and on the editorial boards of Open Journal of Neurology and Open Journal of Neurosurgery; has a patent pending re: MRPS6 Gene in PD; is employed as Senior Medical Director, Medical Affairs for Allergan, Inc.; and owns stock in Allergan, Inc. and Biogen Idec. Dr. Pahwa has served on scientific advisory boards and as a consultant for Teva Pharmaceutical Industries Ltd., Merck Serono, Schering-Plough Corp., Novartis, Medtronic, Inc., GE Healthcare, Biogen Idec, Boehringer Ingelheim, IMPAX Laboratories, Inc., and Ceregene; serves as Co-Editor in Chief of the International Journal of Neuroscience; receives publishing royalties for Pocket Note Series (Oxford University Press, 2009, 2010); serves on speakers' bureaus for Teva Pharmaceutical Industries Ltd., Medtronic, Inc., GlaxoSmithKline, and Novartis; receives research support from GlaxoSmithKline, Novartis, IMPAX Laboratories, Inc., Merck Serono, Boehringer Ingelheim, Schering-Plough Corp., the NIH/NINDS, and the National Parkinson Foundation; and served as an expert witness in a welding-related legal case. Dr. Lyons serves on a scientific advisory board for St. Jude Medical; serves as Co-Editor in Chief for the International Journal of Neuroscience; and serves as a consultant for Teva Pharmaceutical Industries Ltd. and Novartis. Dr. Uitti serves as an Associate Editor of Neurology{\textregistered}; has received research support from Advanced Neuromodulations Systems and from the NIH; and his institution receives annual royalties from Lundbeck Inc. from the licensing of the technology related to PARK8/LRRK2. Dr. Wszolek serves as Co-Editor-in-Chief of Parkinsonism and Related Disorders, Regional Editor of the European Journal of Neurology, and on the editorial boards of Neurologia i Neurochirurgia Polska, Advances in Rehabilitation, the Medical Journal of the Rzeszow University, and Clinical and Experimental Medical Letters; holds and has contractual rights for receipt of future royalty payments from patents re: A novel polynucleotide involved in heritable Parkinson's disease; receives royalties from publishing Parkinsonism and Related Disorders (Elsevier, 2007, 2008, 2009), and the European Journal of Neurology (Wiley-Blackwell, 2007, 2008, 2009); and receives research support from Allergan, Inc., the NIH, the Pacific Alzheimer Research Foundation (Canada), the CIHR, the Mayo Clinic Florida Research Committee CR program, and the gift from Carl Edward Bolch, Jr., and Susan Bass Bolch. Dr. Dickson serves on the editorial boards of the American Journal of Pathology, Journal of Neuropathology and Experimental Neurology, Brain Pathology, Neurobiology of Aging, Journal of Neurology Neurosurgery and Psychiatry, Annals of Neurology, and Neuropathology; and receives research support from the NIH. Dr. Farrer serves on a scientific advisory board for the Michael J. Fox Foundation; serves/has served on the editorial boards of Neurobiology of Disease and Parkinsonism and Related Disorders; is co-inventor on patents re: LRRK2 gene and mutations; receives institutional research support from Lundbeck Inc.; has received research support from the NIH ( NS40256 [Project and Core PI]), the Pacific Alzheimer Research Foundation, and the Michael J Fox Foundation; and his institution receives annual royalties from Lundbeck Inc. from the licensing of the technology related to PARK8/LRRK2. Dr. Ross serves on the editorial board of Open Longevity Science. Funding Information: Study funding: Supported by NIH/NINDS P50 NS40256 and P01AG017216 , the family of Carl and Susan Bolch, and a Mayo Clinic Florida Research Committee Essential Tremor grant. ",

year = "2011",

month = feb,

day = "15",

doi = "10.1212/WNL.0b013e31820c30c1",

language = "English (US)",

volume = "76",

pages = "670--672",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

TY - JOUR

T1 - MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy

AU - Vilariño-Güell, C.

AU - Soto-Ortolaza, A. I.

AU - Rajput, A.

AU - Mash, D. C.

AU - Papapetropoulos, S.

AU - Pahwa, R.

AU - Lyons, K. E.

AU - Uitti, R. J.

AU - Wszolek, Z. K.

AU - Dickson, D. W.

AU - Farrer, M. J.

AU - Ross, O. A.

N1 - Funding Information: Disclosure: Dr. Vilariño-Güell and Dr. Soto-Ortolaza report no disclosures. Dr. Rajput has served on scientific advisory boards for Novartis and UCB; has received funding for travel and speaker honoraria from Novartis; serves on the editorial board of the Canadian Journal of Neurological Sciences; and has received research support from Novartis, Allergan Inc., the NIH (NINDS U01 NS050324-01A1 [local PI]), CIHR, International Essential Tremor Foundation, Regina Curling Classic for Parkinson's Research, and Parkinson's disease and movement disorders endowment through RUH Foundation. Dr. Mash serves on scientific advisory boards for NIH PMDA, Boris Sokolov, and SRA; has received funding for travel or speaker honoraria from the Institute for the Prevention of In Custody Deaths; has patents pending re: Noribogaine and Biomarkers of Parkinson disease; is employed as Chief Scientific Officer for DEMERx Inc., and serves as a consultant for Phylogeny, Inc. Dr. Papapetropoulos serves as Associate Editor for Yearbook of Neurology and on the editorial boards of Open Journal of Neurology and Open Journal of Neurosurgery; has a patent pending re: MRPS6 Gene in PD; is employed as Senior Medical Director, Medical Affairs for Allergan, Inc.; and owns stock in Allergan, Inc. and Biogen Idec. Dr. Pahwa has served on scientific advisory boards and as a consultant for Teva Pharmaceutical Industries Ltd., Merck Serono, Schering-Plough Corp., Novartis, Medtronic, Inc., GE Healthcare, Biogen Idec, Boehringer Ingelheim, IMPAX Laboratories, Inc., and Ceregene; serves as Co-Editor in Chief of the International Journal of Neuroscience; receives publishing royalties for Pocket Note Series (Oxford University Press, 2009, 2010); serves on speakers' bureaus for Teva Pharmaceutical Industries Ltd., Medtronic, Inc., GlaxoSmithKline, and Novartis; receives research support from GlaxoSmithKline, Novartis, IMPAX Laboratories, Inc., Merck Serono, Boehringer Ingelheim, Schering-Plough Corp., the NIH/NINDS, and the National Parkinson Foundation; and served as an expert witness in a welding-related legal case. Dr. Lyons serves on a scientific advisory board for St. Jude Medical; serves as Co-Editor in Chief for the International Journal of Neuroscience; and serves as a consultant for Teva Pharmaceutical Industries Ltd. and Novartis. Dr. Uitti serves as an Associate Editor of Neurology®; has received research support from Advanced Neuromodulations Systems and from the NIH; and his institution receives annual royalties from Lundbeck Inc. from the licensing of the technology related to PARK8/LRRK2. Dr. Wszolek serves as Co-Editor-in-Chief of Parkinsonism and Related Disorders, Regional Editor of the European Journal of Neurology, and on the editorial boards of Neurologia i Neurochirurgia Polska, Advances in Rehabilitation, the Medical Journal of the Rzeszow University, and Clinical and Experimental Medical Letters; holds and has contractual rights for receipt of future royalty payments from patents re: A novel polynucleotide involved in heritable Parkinson's disease; receives royalties from publishing Parkinsonism and Related Disorders (Elsevier, 2007, 2008, 2009), and the European Journal of Neurology (Wiley-Blackwell, 2007, 2008, 2009); and receives research support from Allergan, Inc., the NIH, the Pacific Alzheimer Research Foundation (Canada), the CIHR, the Mayo Clinic Florida Research Committee CR program, and the gift from Carl Edward Bolch, Jr., and Susan Bass Bolch. Dr. Dickson serves on the editorial boards of the American Journal of Pathology, Journal of Neuropathology and Experimental Neurology, Brain Pathology, Neurobiology of Aging, Journal of Neurology Neurosurgery and Psychiatry, Annals of Neurology, and Neuropathology; and receives research support from the NIH. Dr. Farrer serves on a scientific advisory board for the Michael J. Fox Foundation; serves/has served on the editorial boards of Neurobiology of Disease and Parkinsonism and Related Disorders; is co-inventor on patents re: LRRK2 gene and mutations; receives institutional research support from Lundbeck Inc.; has received research support from the NIH ( NS40256 [Project and Core PI]), the Pacific Alzheimer Research Foundation, and the Michael J Fox Foundation; and his institution receives annual royalties from Lundbeck Inc. from the licensing of the technology related to PARK8/LRRK2. Dr. Ross serves on the editorial board of Open Longevity Science. Funding Information: Study funding: Supported by NIH/NINDS P50 NS40256 and P01AG017216 , the family of Carl and Susan Bolch, and a Mayo Clinic Florida Research Committee Essential Tremor grant.

PY - 2011/2/15

Y1 - 2011/2/15

UR - http://www.scopus.com/inward/record.url?scp=79951606291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951606291&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e31820c30c1

DO - 10.1212/WNL.0b013e31820c30c1

M3 - Article

C2 - 21321341

AN - SCOPUS:79951606291

VL - 76

SP - 670

EP - 672

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7

ER -

MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this